Zobrazeno 21 - 30
of 1 198
pro vyhledávání: '"Afd Pharmacoepi & Clinical Pharmacology"'
Autor:
de Jong, Corine, Herder, Gerarda J M, van Haarlem, Simone W A, van der Meer, Femke S, van Lindert, Anne S R, Ten Heuvel, Alexandra, Brouwer, Jan, Egberts, Toine C G, Deneer, Vera H M, Pharmacoepidemiology and Clinical Pharmacology, Afd Pharmacoepi & Clinical Pharmacology
Publikováno v:
Genes; Volume 14; Issue 1; Pages: 170
Genes, 14(1), 1. Multidisciplinary Digital Publishing Institute (MDPI)
Genes, 14(1), 1. Multidisciplinary Digital Publishing Institute (MDPI)
Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common, disabling side effect in non-small cell lung cancer (NSCLC) patients treated with platinum-based therapy. There is increasing evidence for associations between genetic variant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7437b6be71fbcaff39b6bcd18be6e717
https://dspace.library.uu.nl/handle/1874/426999
https://dspace.library.uu.nl/handle/1874/426999
Autor:
Willame, C, Dodd, C, Durán, C E, Elbers, Rjhj, Gini, R, Bartolini, C, Paoletti, O, Wang, L, Ehrenstein, V, Kahlert, J, Haug, U, Schink, T, Diez-Domingo, J, Mira-Iglesias, A, Carreras, J J, Vergara-Hernández, C, Giaquinto, C, Barbieri, E, Stona, L, Huerta, C, Martín-Pérez, M, García-Poza, P, de Burgos, A, Martínez-González, M, Bryant, V, Villalobos, F, Pallejà-Millán, M, Aragón, M, Souverein, P, Thurin, N H, Weibel, D, Klungel, O H, Sturkenboom, McJm, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
Vaccine, 41(1), 251. Elsevier
Willame, C, Dodd, C, Durán, C E, Elbers, R J H J, Gini, R, Bartolini, C, Paoletti, O, Wang, L, Ehrenstein, V, Kahlert, J, Haug, U, Schink, T, Diez-Domingo, J, Mira-Iglesias, A, Carreras, J J, Vergara-Hernández, C, Giaquinto, C, Barbieri, E, Stona, L, Huerta, C, Martín-Pérez, M, García-Poza, P, de Burgos, A, Martínez-González, M, Bryant, V, Villalobos, F, Pallejà-Millán, M, Aragón, M, Souverein, P, Thurin, N H, Weibel, D, Klungel, O H & Sturkenboom, M C J M 2023, ' Background rates of 41 adverse events of special interest for COVID-19 vaccines in 10 European healthcare databases-an ACCESS cohort study ', Vaccine, vol. 41, no. 1, pp. 251-262 . https://doi.org/10.1016/j.vaccine.2022.11.031
Vaccine, 41(1):251-262
Willame, C, Dodd, C, Durán, C E, Elbers, R J H J, Gini, R, Bartolini, C, Paoletti, O, Wang, L, Ehrenstein, V, Kahlert, J, Haug, U, Schink, T, Diez-Domingo, J, Mira-Iglesias, A, Carreras, J J, Vergara-Hernández, C, Giaquinto, C, Barbieri, E, Stona, L, Huerta, C, Martín-Pérez, M, García-Poza, P, de Burgos, A, Martínez-González, M, Bryant, V, Villalobos, F, Pallejà-Millán, M, Aragón, M, Souverein, P, Thurin, N H, Weibel, D, Klungel, O H & Sturkenboom, M C J M 2023, ' Background rates of 41 adverse events of special interest for COVID-19 vaccines in 10 European healthcare databases-an ACCESS cohort study ', Vaccine, vol. 41, no. 1, pp. 251-262 . https://doi.org/10.1016/j.vaccine.2022.11.031
Vaccine, 41(1):251-262
Background: In May 2020, the ACCESS (The vACCine covid-19 monitoring readinESS) project was launched to prepare real-world monitoring of COVID-19 vaccines. Within this project, this study aimed to generate background incidence rates of 41 adverse eve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f716ac916a612d00d92fdb689adaaf3
https://dspace.library.uu.nl/handle/1874/426989
https://dspace.library.uu.nl/handle/1874/426989
Autor:
Visscher, Boudewijn B., Heerdink, Eibert R., Rademakers, Jany, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
The International Journal of Pharmacy Practice, 31(1), 46. Pharmaceutical Press
International Journal of Pharmacy Practice, 31(1), 46-54. Pharmaceutical Press
International Journal of Pharmacy Practice, 31(1), 46-54. Pharmaceutical Press
Objectives Most currently available medication self-management support tools do not meet the needs of patients with limited health literacy. Recently, tools that are better tailored to the needs of patients with limited health literacy have been deve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c6e39ffff4f7a6042628887e5fbc8dd
https://dspace.library.uu.nl/handle/1874/427963
https://dspace.library.uu.nl/handle/1874/427963
Autor:
Hackert, Mariska Q N, van Uden-Kraan, Cornelia F, Agterof, Mariette J, van der Velden, Annette W G, Vriens, Birgit E P J, Janssen, Johan J B, Geenen, Maud, van der Padt-Pruijsten, Annemieke, van de Garde, Ewoudt M W, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
Cancer Treatment and Research Communications, 35. Elsevier Ltd
INTRODUCTION: In addition to clinical trials, real-world data is needed to verify the effectiveness of the CDK 4/6 inhibitor palbociclib. The primary aim was to examine real-world variation in treatment modification strategies for neutropenia and its
Autor:
Callenbach, Marcelien H.E., Ádám, Lldikó, Vreman, Rick A., Németh, Bertalan, Kaló, Zoltán, Goettsch, Wim G., Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
Drug Discovery Today, 28(1), 1. Elsevier Ltd
There is growing interest in innovative reimbursement and payment models in Central and Eastern European (CEE) and Middle Eastern (ME) countries. A questionnaire was sent to payers from CEE and ME countries regarding the current use of, future prefer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c4222bc0946feb1a819cd0a102be404
https://dspace.library.uu.nl/handle/1874/426992
https://dspace.library.uu.nl/handle/1874/426992
Autor:
Callenbach, Marcelien H E, Vreman, Rick A, Mantel-Teeuwisse, Aukje K, Goettsch, Wim G, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
International Journal of Environmental Research and Public Health; Volume 20; Issue 1; Pages: 340
International Journal of Environmental Research and Public Health, 20(1). MDPI AG
International Journal of Environmental Research and Public Health, 20(1). MDPI AG
This study aimed to identify the current experiences with and future preferences for payment and reimbursement models for high-priced hospital therapies in the Netherlands, where the main barriers lie and assess how policy structures facilitate these
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d6daff2c388c255ad93140efb6223e2
https://dspace.library.uu.nl/handle/1874/426534
https://dspace.library.uu.nl/handle/1874/426534
Autor:
Eroglu, Talip E., Coronel, Ruben, Zuurbier, Coert J., Blom, Marieke, de Boer, Anthonius, Souverein, Patrick C., Afd Pharmacoepi & Clinical Pharmacology, Sub Gen. Pharmacoepi and Clinical Pharm, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
European heart journal. Cardiovascular pharmacotherapy, 9(1), 18-25. Oxford University Press
European heart journal. Cardiovascular pharmacotherapy, 9(1), 18. NLM (Medline)
Eroglu, T E, Coronel, R, Zuurbier, C J, Blom, M, de Boer, A & Souverein, P C 2022, ' Use of sodium-glucose cotransporter-2 inhibitors and the risk for sudden cardiac arrest and for all-cause death in patients with type 2 diabetes mellitus ', European heart journal. Cardiovascular pharmacotherapy, vol. 9, no. 1, pp. 18-25 . https://doi.org/10.1093/ehjcvp/pvac043
European heart journal. Cardiovascular pharmacotherapy, 9(1), 18. NLM (Medline)
Eroglu, T E, Coronel, R, Zuurbier, C J, Blom, M, de Boer, A & Souverein, P C 2022, ' Use of sodium-glucose cotransporter-2 inhibitors and the risk for sudden cardiac arrest and for all-cause death in patients with type 2 diabetes mellitus ', European heart journal. Cardiovascular pharmacotherapy, vol. 9, no. 1, pp. 18-25 . https://doi.org/10.1093/ehjcvp/pvac043
Aims Sodium-glucose cotransporter-2 inhibitors (SGLT-2is) are antidiabetic agents that can have direct cardiac effects by impacting on cardiac ion transport mechanisms that control cardiac electrophysiology. We studied the association between SGLT-2i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3fbafda5257249edae604a66d872c7e
https://research.vumc.nl/en/publications/291398a0-7c45-47e0-b8e0-035837b65811
https://research.vumc.nl/en/publications/291398a0-7c45-47e0-b8e0-035837b65811
Autor:
Sallevelt, Bastiaan T.G.M., Egberts, Toine C.G., Huibers, Corlina J.A., Ietswaart, Jimmy, Drenth-van Maanen, A. Clara, Jennings, Emma, O’Mahony, Cian, Jungo, Katharina Tabea, Feller, Martin, Rodondi, Nicolas, Sibille, François Xavier, Spinewine, Anne, van Puijenbroek, Eugène P., Wilting, Ingeborg, Knol, Wilma, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
Sallevelt, Bastiaan T G M; Egberts, Toine C G; Huibers, Corlina J A; Ietswaart, Jimmy; Drenth-van Maanen, A Clara; Jennings, Emma; O'Mahony, Cian; Jungo, Katharina Tabea; Feller, Martin; Rodondi, Nicolas; Sibille, François-Xavier; Spinewine, Anne; van Puijenbroek, Eugène P; Wilting, Ingeborg; Knol, Wilma (2022). Detectability of Medication Errors With a STOPP/START-Based Medication Review in Older People Prior to a Potentially Preventable Drug-Related Hospital Admission. Drug safety, 45(12), pp. 1501-1516. Springer 10.1007/s40264-022-01237-5
Drug Safety, Vol. 45, no. 12, p. 1501-1516 (2022)
Drug Safety, 45(12), 1501-1516. ADIS INT LTD
Drug Safety, 45(12), 1501. Springer International Publishing Switzerland
Drug Safety, Vol. 45, no. 12, p. 1501-1516 (2022)
Drug Safety, 45(12), 1501-1516. ADIS INT LTD
Drug Safety, 45(12), 1501. Springer International Publishing Switzerland
Introduction: Multimorbidity and polypharmacy are risk factors for drug-related hospital admissions (DRAs) in the ageing population. DRAs caused by medication errors (MEs) are considered potentially preventable. The STOPP/START criteria were develope
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::672f3898b660657eeff946433fea2c39
https://boris.unibe.ch/174450/8/Sallevelt_DrugSaf_2022.pdf
https://boris.unibe.ch/174450/8/Sallevelt_DrugSaf_2022.pdf
Autor:
Schoenmakers, Daphne H, Beerepoot, Shanice, van den Berg, Sibren, Adang, Laura, Bley, Annette, Boelens, Jaap-Jan, Fumagalli, Francesca, Goettsch, Wim G, Grønborg, Sabine, Groeschel, Samuel, van Hasselt, Peter M, Hollak, Carla E M, Lindemans, Caroline, Mochel, Fanny, Mol, Peter G M, Sevin, Caroline, Zerem, Ayelet, Schöls, Ludger, Wolf, Nicole I, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
Orphanet Journal of Rare Diseases, 17(1):48. BioMed Central
Orphanet journal of rare diseases, 17(1):48. BioMed Central
Orphanet journal of rare diseases, 17(1):48. BMC
Orphanet Journal of Rare Diseases, 17(1), 1. BioMed Central
Orphanet journal of rare diseases 17(1), 48 (2022). doi:10.1186/s13023-022-02189-w
Schoenmakers, D H, Beerepoot, S, van den Berg, S, Adang, L, Bley, A, Boelens, J-J, Fumagalli, F, Goettsch, W G, Grønborg, S, Groeschel, S, van Hasselt, P M, Hollak, C E M, Lindemans, C, Mochel, F, Mol, P G M, Sevin, C, Zerem, A, Schöls, L & Wolf, N I 2022, ' Modified Delphi procedure-based expert consensus on endpoints for an international disease registry for Metachromatic Leukodystrophy : The European Metachromatic Leukodystrophy initiative (MLDi) ', Orphanet Journal of Rare Diseases, vol. 17, no. 1, 48, pp. 48 . https://doi.org/10.1186/s13023-022-02189-w
Orphanet journal of rare diseases, 17(1):48. BioMed Central
Orphanet journal of rare diseases, 17(1):48. BMC
Orphanet Journal of Rare Diseases, 17(1), 1. BioMed Central
Orphanet journal of rare diseases 17(1), 48 (2022). doi:10.1186/s13023-022-02189-w
Schoenmakers, D H, Beerepoot, S, van den Berg, S, Adang, L, Bley, A, Boelens, J-J, Fumagalli, F, Goettsch, W G, Grønborg, S, Groeschel, S, van Hasselt, P M, Hollak, C E M, Lindemans, C, Mochel, F, Mol, P G M, Sevin, C, Zerem, A, Schöls, L & Wolf, N I 2022, ' Modified Delphi procedure-based expert consensus on endpoints for an international disease registry for Metachromatic Leukodystrophy : The European Metachromatic Leukodystrophy initiative (MLDi) ', Orphanet Journal of Rare Diseases, vol. 17, no. 1, 48, pp. 48 . https://doi.org/10.1186/s13023-022-02189-w
Background Metachromatic Leukodystrophy (MLD) is a rare lysosomal disorder. Patients suffer from relentless neurological deterioration leading to premature death. Recently, new treatment modalities, including gene therapy and enzyme replacement thera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7265016fd8f71a910e6169d7939c63c
https://research.vumc.nl/en/publications/d77d6490-e523-48bb-b674-b2525614b224
https://research.vumc.nl/en/publications/d77d6490-e523-48bb-b674-b2525614b224
Autor:
Sarodnik, Cindy, Rasmussen, Nicklas H., Bours, Sandrine P.G., Schaper, Nicolaas C., Vestergaard, Peter, Souverein, Patrick C., Jensen, Morten H., Driessen, Johanna H.M., van den Bergh, Joop P.W., Afd Pharmacoepi & Clinical Pharmacology, Sub Gen. Pharmacoepi and Clinical Pharm, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
Bone Reports, 17:101614. Elsevier Inc.
Bone Reports, 17, 1. Elsevier
Sarodnik, C, Rasmussen, N H, Bours, S P G, Schaper, N C, Vestergaard, P, Souverein, P C, Jensen, M H, Driessen, J H M & van den Bergh, J P W 2022, ' The incidence of fractures at various sites in newly treated patients with Type 2 Diabetes Mellitus ', Bone Reports, vol. 17, 101614 . https://doi.org/10.1016/j.bonr.2022.101614
Bone Reports, 17, 1. Elsevier
Sarodnik, C, Rasmussen, N H, Bours, S P G, Schaper, N C, Vestergaard, P, Souverein, P C, Jensen, M H, Driessen, J H M & van den Bergh, J P W 2022, ' The incidence of fractures at various sites in newly treated patients with Type 2 Diabetes Mellitus ', Bone Reports, vol. 17, 101614 . https://doi.org/10.1016/j.bonr.2022.101614
Purpose: In this descriptive study, we examined the incidence of fractures in patients with newly treated type 2 diabetes mellitus (T2D) compared to matched reference population.Methods: Participants from the UK Clinical Practice research datalink (C